Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 62Gastrointestinal 33Genitourinary 24Head & Neck 18Breast 17Gynecologic 16Lymphoid 9Other solid neoplasm 8Sarcoma 6Plasma cell 4Tumor-Agnostic 3Other hematologic neoplasm 3Endocrine 3CNS 3Dermatologic 2NET 1Myeloid 1

Conditions

Neoplasms 1Myelodysplastic Syndromes 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Lymphatic Diseases 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoproliferative Disorders 1Immune System Diseases 1Hodgkin Disease 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 296Cytarabine 261fludarabine phosphate 218Rituximab 195fludarabine 182Methotrexate 152Whole-Body Irradiation 140Mycophenolic Acid 124Azacitidine 122Tacrolimus 116Busulfan 110Filgrastim 104Granulocyte Colony-Stimulating Factor 98Etoposide 91Peripheral Blood Stem Cell Transplantation 90Dexamethasone 89Vincristine 88Melphalan 80Cyclosporine 74Lenalidomide 73Daunorubicin 70Decitabine 69Clofarabine 69Antilymphocyte Serum 67Calcium Dobesilate 61venetoclax 60Doxorubicin 58Imatinib Mesylate 57Alemtuzumab 56ibrutinib 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × durvalumab × Other hematologic neoplasm × Clear all
NCT03837899 2026-04-21

Durvalumab and Tremelimumab for Pediatric Malignancies

AstraZeneca

Phase 1/2 Active not recruiting
50 enrolled 59 charts
Other hematologic neoplasm

Neoplasms, Hematologic Neoplasms

NCT02733042 2023-11-18

FUSION NHL 001

Celgene

Phase 1/2 Completed
106 enrolled 48 charts
LymphoidOther hematologic neoplasm

Hodgkin Disease, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT02775903 2023-02-28

An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)

Celgene

Phase 2 Completed
213 enrolled 35 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡